Announcements Trials
Browse Landscape

Phase

Phase 2 139Phase 1 114Phase 3 61Phase 1/2 55Phase 2/3 5Phase EARLY_PHASE1 4Phase NA 2

Status

Active not recruiting 3Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 2OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Thymoma 1Thymic epithelial tumor 1Myasthenia Gravis 1Mediastinal Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Autoimmune Diseases 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 14Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 8Radiation 8Platinum 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Pemetrexed 7Drug Therapy 7Dexamethasone 7Temozolomide 6Ipilimumab 6Surgical Procedures, Operative 5Rituximab 5Radiotherapy, Intensity-Modulated 5Prednisone 5Cytarabine 5Cyclophosphamide 5Biopsy 5130-nm albumin-bound paclitaxel 5venetoclax 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Cyclophosphamide × 90 days × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02405676 2026-03-19

BNHL-2015

Children's Cancer Group, China

Phase 2/3 Active not recruiting
200 enrolled
Lymphoid

Lymphoma

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Not yet recruiting
116 enrolled
Thoracic

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡